Year Month Index value Company price Dividend Info

January 4,136.31 173.3

February 3,973.28 175.6
March 3,590.05 178.6
April 3,438.90 179.5
May 3,878.07 196.4
June 4,104.65 220
July 3,940.81 211.4
August 4,127.48 169.9 2.5
September 3,937.68 173.9
October 3,967.73 179.9
November 4,230.73 193.3
2013 December 4,266.55 190.2
January 4,753.17 228.4
February 4,749.87 265.7
March 4,491.98 267
April 4,566.86 281.7
May 4,430.48 270
June 4,480.52 282.2
July 4,427.16 255.3
August 4,549.52 234.4 3
September 5,074.31 260.6
October 5,173.23 278.7
November 4,769.43 251.9
2014 December 4,864.96 258.5
January 4,724.05 254.3
February 4,624.95 263.8
March 4,530.48 263.1
April 4,047.29 246
May 4,586.95 246.6
June 4,583.11 262.2
July 4,792.31 272.7
August 4,768.67 252.9 3
September 4,852.08 249.4
October 4,564.49 243
November 4,581.00 254.1
2015 December 4,629.64 253.7
January 4,540.89 258.9
February 4,511.97 263.5
March 4,357.54 250.7
April 4,195.70 253.4
May 4,419.39 260.3
June 4,507.58 265.7
 July 4,525.35 267.1
August 4,526.58 262.3
September 4,695.19 268.6
October 4,592.18 267.8
November 4,801.24 244.9 4
2016 December 5,036.05 249.1
January 5,468.34 259.9
February 5,612.70 268.2
March 5,719.61 277.9
2017 April 5,475.55 283.7

Risk-free rate 7.000%

Rm - Market return monthly 0.685%
Rm - Annualized market return 8.219%
Market risk premium 1.219%
COV (Rm, Ri) 0.0017
VAR (Rm) 0.0028
Beta 0.61
Adjusted Beta 0.74
Ke - CAPM 7.90%
Bonus share Adjustment Dividend Yield Capital Gain Square Return Market Return
1
1 0.00% 1.33% 1.33% -3.94%
1 0.00% 1.71% 1.71% -9.65%
1 0.00% 0.50% 0.50% -4.21%
1 0.00% 9.42% 9.42% 12.77%
1 0.00% 12.02% 12.02% 5.84%
1 0.00% -3.91% -3.91% -3.99%
1.3 1.18% 4.48% 5.66% 4.74%
1 0.00% 2.35% 2.35% -4.60%
1 0.00% 3.45% 3.45% 0.76%
1 0.00% 7.45% 7.45% 6.63%
1 0.00% -1.60% -1.60% 0.85%
1 0.00% 20.08% 20.08% 11.41%
1 0.00% 16.33% 16.33% -0.07%
1 0.00% 0.49% 0.49% -5.43%
1 0.00% 5.51% 5.51% 1.67%
1 0.00% -4.15% -4.15% -2.99%
1 0.00% 4.52% 4.52% 1.13%
1 0.00% -9.53% -9.53% -1.19%
1.15 1.18% 5.59% 6.76% 2.76%
1 0.00% 11.18% 11.18% 11.54%
1 0.00% 6.95% 6.95% 1.95%
1 0.00% -9.62% -9.62% -7.81%
1 0.00% 2.62% 2.62% 2.00%
1 0.00% -1.62% -1.62% -2.90%
1 0.00% 3.74% 3.74% -2.10%
1 0.00% -0.27% -0.27% -2.04%
1 0.00% -6.50% -6.50% -10.67%
1 0.00% 0.24% 0.24% 13.33%
1 0.00% 6.33% 6.33% -0.08%
1 0.00% 4.00% 4.00% 4.56%
1.125 1.10% 4.33% 5.43% -0.49%
1 0.00% -1.38% -1.38% 1.75%
1 0.00% -2.57% -2.57% -5.93%
1 0.00% 4.57% 4.57% 0.36%
1 0.00% -0.16% -0.16% 1.06%
1 0.00% 2.05% 2.05% -1.92%
1 0.00% 1.78% 1.78% -0.64%
1 0.00% -4.86% -4.86% -3.42%
1 0.00% 1.08% 1.08% -3.71%
1 0.00% 2.72% 2.72% 5.33%
1 0.00% 2.07% 2.07% 2.00%
 1 0.00% 0.53% 0.53% 0.39%
1 0.00% -1.80% -1.80% 0.03%
1 0.00% 2.40% 2.40% 3.72%
1 0.00% -0.30% -0.30% -2.19%
1.1 1.49% 0.59% 2.09% 4.55%
1 0.00% 1.71% 1.71% 4.89%
1 0.00% 4.34% 4.34% 8.58%
1 0.00% 3.19% 3.19% 2.64%
1 0.00% 3.62% 3.62% 1.90%
1 0.00% 2.09% 2.09% -4.27%
 Particulars 2012
Net Turnover 16,054,425,243
% in Net Turnover
Mean
Standad Deviation
CV
EBIT 3,321,146,713
% in EBIT
DOL

Note 1: Square exports less than 5% of its products; 95% of it

Note 2: Square's capital structure does not have any debt; so
Note 3: Upto 2032, Bangladesh based Pharmaceutical Indust
 2013 2014 2015 2016
17,959,489,496 23,268,413,217 26,684,573,116 31,482,540,352
11.87% 29.56% 14.68% 17.98%
23,089,888,285
6308901862.70175
27.32%
3,852,810,574 5,967,653,270 7,049,611,578 9,981,101,833
16.01% 54.89% 18.13% 41.58%
1.35 1.86 1.23 2.31

than 5% of its products; 95% of its pharmaceutical products serve the local market.
cture does not have any debt; so it is not exposed to financial risk.
esh based Pharmaceutical Industry is free from TRIPS based patent restictions.